Safety of treatment with biologics for psoriasis in daily practice: 5-year data

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register

(2010) A. A. Saad et al.   RHEUMATOLOGY

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

(2009) G R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden

(2009) J Ji et al.   BRITISH JOURNAL OF CANCER

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

(2009) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome

(2009) R.J.B. Driessen et al.   BRITISH JOURNAL OF DERMATOLOGY

A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration Database

(2009) J. D. CARTER et al.   JOURNAL OF RHEUMATOLOGY

Treatments for psoriasis and the risk of malignancy

(2009) Rita V. Patel et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

(2009) D Pathirana et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome

(2008) R.J.B. Driessen et al.   BRITISH JOURNAL OF DERMATOLOGY

The Continuous Morbidity Registration Nijmegen: Background and history of a Dutch general practice database

(2008) Chris Van Weel   European Journal of General Practice